aTYR PHARMA INC

ATYRSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1339970

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$353.0K	$10.4M	$0.00	$10.5M	$422.0K
Research and Development Expense	$42.3M	$42.8M	$23.3M	$17.3M	$14.0M
Operating Expenses	$55.3M	$56.8M	$34.0M	$26.4M	$23.4M
Operating Income (Loss)	-$54.9M	-$46.4M	-$34.0M	-$15.9M	-$23.0M
Nonoperating Income (Expense)	$4.5M	$1.1M	$238.0K	-$319.0K	-$785.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$50.4M	-$45.3M	-$33.8M	-$16.2M	-$23.8M
Income Tax Expense (Benefit)	$0.00	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$96.8M	$120.7M	$95.8M	$115.5M	$38.7M
Assets, Current	$82.0M	$103.0M	$80.9M	$113.6M	$35.5M
Cash and Cash Equivalents, at Carrying Value	$22.5M	$10.0M	$2.3M	$17.0M	$17.0M
Liabilities, Current	$15.0M	$16.4M	$13.9M	$6.0M	$5.9M
Long-term Debt, Excluding Current Maturities	—	—	—	—	—
Accounts Payable, Current	$4.3M	$3.5M	$3.1M	$1.0M	$1.4M
Stockholders' Equity Attributable to Parent	$70.0M	$90.7M	$71.5M	$109.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$33.2M	-$41.9M	-$33.1M	-$15.3M	-$20.0M
Net Cash Provided by (Used in) Investing Activities	-$20.1M	$47.2M	-$91.6M	$6.9M	$4.9M
Net Cash Provided by (Used in) Financing Activities	$66.2M	$5.5M	$110.0M	$16.1M	$1.3M
Payments to Acquire Property, Plant, and Equipment	$4.2M	$1.6M	$192.0K	$202.0K	$79.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)